Efficacy and Safety of First-Line Platinum-Based Doublet Chemotherapy in Advanced Primary Pulmonary Salivary Gland Tumors (PSGTs).

IF 1.8 4区医学 Q3 ONCOLOGY

Cancer Investigation Pub Date : 2024-10-01 Epub Date: 2024-09-16 DOI:10.1080/07357907.2024.2399046

Zheng Shi, Xiaohong Zeng, Wei Sun, Manyi Xu, Keda Shao, Jingwen Wei, Chunwei Xu, Zhengbo Song

引用次数: 0

Abstract

Primary pulmonary salivary gland tumors (PSGT) constitute a rare subtype of non-small cell lung cancer (NSCLC). Currently, no established treatment guidelines exist for advanced PSGT. The efficacy of platinum-based chemotherapy for PSGT within the context of NSCLC remains uncertain. Therefore, we retrospectively collected 37 PSGT patients who underwent first-line platinum-based chemotherapy from 2010 to 2023. Survival analysis, employing the Kaplan-Meier method, and group comparisons via the log rank test were conducted. Our results show that first-line platinum-based chemotherapy demonstrates favorable efficacy and manageable safety in advanced PSGT, with the combination of Paclitaxel + Platinum emerging as a preferred option.

查看原文本刊更多论文

晚期原发性肺唾液腺肿瘤（PSGTs）一线铂基双联化疗的有效性和安全性

原发性肺唾液腺肿瘤（PSGT）是非小细胞肺癌（NSCLC）的一种罕见亚型。目前，还没有针对晚期肺唾液腺肿瘤的既定治疗指南。以铂类为基础的化疗对 NSCLC 中的 PSGT 的疗效仍不确定。因此，我们回顾性地收集了2010年至2023年期间接受一线铂类化疗的37例PSGT患者。我们采用 Kaplan-Meier 法进行了生存期分析，并通过对数秩检验进行了分组比较。我们的研究结果表明，一线铂类化疗对晚期PSGT具有良好的疗效和可控的安全性，紫杉醇+铂类联合化疗成为首选方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Investigation 医学-肿瘤学

CiteScore

3.80

自引率

4.20%

发文量

审稿时长

8.5 months

期刊介绍： Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.